Telos Capital Management Inc. Has $1.25 Million Position in Pfizer Inc. (NYSE:PFE)

Telos Capital Management Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 5.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,299 shares of the biopharmaceutical company’s stock after selling 2,564 shares during the quarter. Telos Capital Management Inc.’s holdings in Pfizer were worth $1,247,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PFE. Adage Capital Partners GP L.L.C. increased its stake in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC acquired a new position in shares of Pfizer in the fourth quarter worth $255,000. Brookstone Capital Management increased its position in Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after buying an additional 212,369 shares during the last quarter. ETF Store Inc. increased its position in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 727 shares during the last quarter. Finally, Farmers Trust Co. increased its position in Pfizer by 2.0% during the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after buying an additional 4,410 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Down 1.1 %

NYSE PFE opened at $25.41 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a 50-day simple moving average of $27.19 and a 200 day simple moving average of $28.76. Pfizer Inc. has a twelve month low of $25.26 and a twelve month high of $41.33. The stock has a market cap of $143.86 billion, a PE ratio of 70.57, a PEG ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.14 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.